Please use this identifier to cite or link to this item: https://open.uns.ac.rs/handle/123456789/32459
DC FieldValueLanguage
dc.contributor.authorSusbin Raj Wagleen_US
dc.contributor.authorBožica Kovačevićen_US
dc.contributor.authorDaniel Walkeren_US
dc.contributor.authorCorina Mihaela Ionescuen_US
dc.contributor.authorMelissa Jonesen_US
dc.contributor.authorGoran Stojanovićen_US
dc.contributor.authorSanja Kojićen_US
dc.contributor.authorArmin Mooranianen_US
dc.contributor.authorHani Al-Salamien_US
dc.date.accessioned2022-07-03T12:13:20Z-
dc.date.available2022-07-03T12:13:20Z-
dc.date.issued2020-07-29-
dc.identifier.issn1999-4923en_US
dc.identifier.urihttps://open.uns.ac.rs/handle/123456789/32459-
dc.description.abstractBile acids have recently been studied for potential applications as formulation excipients and enhancers for drug release; however, some bile acids are not suitable for this application. Unconjugated lithocholic acid (ULCA) has recently shown drug formulation-stabilizing and anti-inflammatory effects. Lipophilic drugs have poor gut absorption after an oral dose, which necessitates the administration of high doses and causes subsequent side effects. Probucol (PB) is a highly lipophilic drug with poor oral absorption that resulted in restrictions on its clinical prescribing. Hence, this study aimed to design new delivery systems for PB using ULCA-based matrices and to test drugformulation, release, temperature, and biological effects. ULCA-based matrices were formulated for PB oral delivery by applying the jet-flow microencapsulation technique using sodium alginate as a polymer. ULCA addition to new PB matrices improved the microcapsule’s stability, drug release in vitro (formulation study), and showed a promising effect in ex vivo study (p < 0.05), suggesting that ULCA can optimize the oral delivery of PB and support its potential application in diabetes treatment.en_US
dc.description.sponsorshipEuropean Commissionen_US
dc.language.isoenen_US
dc.publisherMDPIen_US
dc.relationH2020 SALSETHen_US
dc.relation.ispartofPharmaceuticsen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subjectbile acidsen_US
dc.subjectdiabetes mellitusen_US
dc.subjectformulation sciencesen_US
dc.subjectInflammationen_US
dc.subjectprobucolen_US
dc.subjectunconjugated lithocholic aciden_US
dc.titlePharmacological and Advanced Cell Respiration E ects, Enhanced by Toxic Human-Bile Nano-Pharmaceuticals of Probucol Cell-Targeting Formulationsen_US
dc.typeArticleen_US
dc.identifier.doi10.3390/pharmaceutics12080708-
dc.description.versionPublisheden_US
dc.relation.lastpage17en_US
dc.relation.firstpage1en_US
dc.relation.issue708en_US
dc.relation.volume12en_US
item.grantfulltextopen-
item.fulltextWith Fulltext-
crisitem.author.deptFakultet tehničkih nauka, Departman za energetiku, elektroniku i telekomunikacije-
crisitem.author.deptFakultet tehničkih nauka, Departman za energetiku, elektroniku i telekomunikacije-
crisitem.author.orcid0000-0003-2098-189X-
crisitem.author.orcid0000-0002-4092-9733-
crisitem.author.parentorgFakultet tehničkih nauka-
crisitem.author.parentorgFakultet tehničkih nauka-
Appears in Collections:FTN Publikacije/Publications
Files in This Item:
File Description SizeFormat
pharmaceutics-12-00708.pdf1.64 MBAdobe PDFView/Open
Show simple item record

Page view(s)

30
Last Week
4
Last month
0
checked on May 10, 2024

Download(s)

14
checked on May 10, 2024

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons